Eli Lilly and Company (NYSE:LLY) Holdings Raised by APG Asset Management N.V.

APG Asset Management N.V. grew its position in Eli Lilly and Company (NYSE:LLY) by 6.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 703,220 shares of the company’s stock after acquiring an additional 44,133 shares during the quarter. Eli Lilly and Company makes up approximately 1.1% of APG Asset Management N.V.’s holdings, making the stock its 19th largest position. APG Asset Management N.V. owned 0.07% of Eli Lilly and Company worth $594,058,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the company. Lynx Investment Advisory bought a new position in Eli Lilly and Company during the 2nd quarter worth $32,000. LGT Financial Advisors LLC bought a new position in Eli Lilly and Company during the 2nd quarter worth $36,000. Morton Brown Family Wealth LLC grew its stake in Eli Lilly and Company by 45.5% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after buying an additional 15 shares during the last quarter. Core Wealth Advisors Inc. grew its stake in Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after buying an additional 32 shares during the last quarter. Finally, Unique Wealth Strategies LLC bought a new position in Eli Lilly and Company during the 2nd quarter worth $45,000. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Barclays boosted their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and boosted their price target for the stock from $725.00 to $1,025.00 in a research report on Monday, August 12th. Jefferies Financial Group upped their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Wells Fargo & Company upped their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $977.35.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 1,441 shares of the company’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $915.02, for a total value of $1,318,543.82. Following the transaction, the insider now directly owns 97,367,369 shares of the company’s stock, valued at approximately $89,093,089,982.38. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 425,000 shares of company stock valued at $394,455,351 in the last three months. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 0.1 %

NYSE:LLY opened at $924.97 on Thursday. The firm has a market capitalization of $879.10 billion, a price-to-earnings ratio of 136.23, a PEG ratio of 2.78 and a beta of 0.42. Eli Lilly and Company has a 1-year low of $516.57 and a 1-year high of $972.53. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The business’s fifty day moving average price is $894.11 and its 200 day moving average price is $840.86.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. On average, sell-side analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.